{"id":1015290,"date":"2026-10-29T12:55:48","date_gmt":"2026-10-29T16:55:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-social-ventures-announced-support-of-no-patient-left-behind-with-six-figure-organizational-legacy-gift\/"},"modified":"2026-10-29T12:55:48","modified_gmt":"2026-10-29T16:55:48","slug":"roivant-social-ventures-announced-support-of-no-patient-left-behind-with-six-figure-organizational-legacy-gift","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-social-ventures-announced-support-of-no-patient-left-behind-with-six-figure-organizational-legacy-gift\/","title":{"rendered":"Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift"},"content":{"rendered":"
\n

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) — Today Roivant Social Ventures (RSV) announced it is joining efforts with No Patient Left Behind (NPLB) to improve drug affordability and access while supporting ongoing medical innovation, through a six-figure legacy donation.<\/strong><\/p>\n

RSV is a 501(c)3 public charity and social impact organization that partners with innovative companies, institutes, and organizations to promote systemic, sustained improvements to the way health care is accessed and delivered. The organization launched with the vision of a world where every person is born with the right and ability to access medicine and medical care, regardless of their geographic location, wealth, or insurance status. In striving for this goal, RSV spent the last six years building out programing to increase access to therapeutics for underserved people, while working to embed these principles throughout the biotechnology and healthcare industries.<\/p>\n

In this next chapter, RSV closes out its own institutional work, while putting full support behind NPLB to\u00a0enhance organizational mission fulfillment, operational efficiency, and community impact.\u00a0<\/p>\n

Lindsay Androksi, RSV Founder and Board President, shared, \u201cI am immensely proud of RSV’s work incubating and investing in early-stage companies and launching and expanding educational and fellowship opportunities for future equity-minded industry leaders. We also co-founded groups working to bring new therapies to underserved patient populations, such as the Global Gene Therapy Initiative and the Catalyzing Access to Research and Equity in Representation Group, and are excited to see those organizations continue their important work.<\/p>\n

I am grateful to Roivant Sciences for enthusiastically supporting the launch of Roivant Social Ventures six years ago and our projects since that time. I can think of no better organization to carry on our legacy than NPLB.\u201d<\/p>\n

\u201cRoivant Social Ventures has opened doors for people who need help accessing medicines,\u201d said Priscilla VanderVeer, Executive Director of No Patient Left Behind. \u201cWe\u2019re honored by this donation, and will continue their legacy as we work to improve affordability while preserving the innovation ecosystem we all rely on.\u201d\u00a0<\/p>\n

About No Patient Left Behind (NPLB)<\/p>\n

NPLB is a network of biotechnology innovators, investors, economists, healthcare professionals, and patients working together to support solutions that improve affordability while preserving the innovation ecosystem we all rely on. NPLB’s work educates stakeholders and policymakers about balanced policy solutions that enable every patient to afford the drugs prescribed by their doctor at low or no out-of-pocket cost \u2014 while also preserving the incentives for investment that spur the development of new, life-saving treatments.<\/p>\n

NPLB’s Goals are to:<\/p>\n